Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Where are they at with their COVID treatment plans?
View:
Post by VerusSemperSors on Nov 27, 2021 8:27am

Where are they at with their COVID treatment plans?

I'm sure that someone out there will have much deeper knowledge on this topic than I have. I believe there was a press release about this work back in January that seemed to promptly pop the SP up 15 or 20%.
Comment by Longholder99 on Nov 27, 2021 10:08am
The fact that the type of vaccine Theralase is collaborating on is not variant dependant should be meaningful. Im alwaya at a loss as to why the market is failing to recognize the tech this company is developing.
Comment by greaterfoolFred on Nov 27, 2021 11:55am
It was my understanding, that for the research being done now, 1433 will be used to kill a virus which will then be purified to produce a vaccine.  Therefore it will be variant dependent, depending on what variant you start with.   If we could use 1433 itself as a drug, eg. injected into the body, then it might be variant independent.  But to use it as a drug, we would first ...more  
Comment by CancerSlayer on Nov 27, 2021 8:34pm
  Creating a universal vaccine for a constantly evolving/mutating RNA virus is a challenge to say the least, & far from being a reality.  Like with the flu vaccine, what works one given year may be ineffective the next...  The hope is by using TLD-1433 (or a newer derivative compound) against "currently circulating" variants, one can produce a vaccine that can ...more  
Comment by wildbird1 on Nov 28, 2021 8:43am
Covid-19 Vaccine... greaterfoolFred, I think that what Longholder99 is referring to when he said " not variant dependant" is in the PressRelease April 9,2021. The PHAC(Public Health Agency Of Canada) said " Our research expertise will help assist TLT to research and develop an effective Covid-19 vaccine that is robust enough to vaccinate against the " main phenotype" of ...more  
Comment by Longholder99 on Nov 28, 2021 9:00am
Exactly Wildbird. Thx
Comment by greaterfoolFred on Nov 28, 2021 12:07pm
Yes Longholder99 and Wildbird, you guys are right about the press release, but I think it was a bit optimistic.  If you make a vaccine by killing a whole virus, then it may be more effective against variants than a mrna vaccine that only makes the spike protein.  But early data (which I hope is wrong) says that the Astrazenica vaccine, which is from whole virus, doesn't seem to be ...more  
Comment by Sosak1 on Nov 28, 2021 2:37pm
If Theralase can give us any positive news from work on Covid  like animal testing or anything that looks even slightly promising, our stock will move upwords big times.
Comment by Oilminerdeluxe on Nov 28, 2021 3:21pm
That's what they did with cancer and look where that got us, lol. But I hope you are right of course.
Comment by CancerSlayer on Nov 28, 2021 3:34pm
  The hope is our whole virus-killing technology can expose unique immunogenic viral antigens (kill me signals).  However, using a killed or inactivated whole virus vaccine without having a proper adjuvant can potentially reduce vaccine efficacy regardless of antigen variant type.  Vaccine adjuvants can play as critical a role in triggering an effective/lasting immune response as ...more  
Comment by Oilminerdeluxe on Nov 27, 2021 1:35pm
I wonder how much worked they have gotten done on this. If any material. Hope so of course.  So quiet on this front, I am not sure what to believe. 
Comment by Pandora on Nov 27, 2021 2:03pm
This is also very interesting - a review of the Pfizer vaccine approval process as written by the New England Journal of Medicine in December, 2020 and it has not been retracted - which probably suggests there is truth to it and it is not "misinformation" - what with the New England Journal of Medicine being a very well recognized organization. Interesting as to how Pfizer got FDA ...more  
Comment by Pandora on Nov 27, 2021 2:19pm
I picked this up off the CYDY board on Yahoo. Just to give rise to how different people perceive things, one of the comments there was, "this has nothing to do with Pfizer, it is just a report about the poor management of a single contract firm out of Texas" - or words to the effect, i.e. not a direct quote.
Comment by Yajne on Nov 27, 2021 3:31pm
Im also surprised that so far no 'grants' have been awarded for such an important initiative. But then again, the 'powers that be' might have assumed that the existing vaccines have provided a  complete solution. Obviously not, and that reality now appears to be emerging again
Comment by Oilminerdeluxe on Nov 27, 2021 4:21pm
Maybe some small update will arrive soon. Hope so, but not counting on it. Wise from past experience. Not much longer to wait for new data
Comment by gojotv! on Nov 29, 2021 2:01am
THIS, among other developments under the TLT umbrella, points to why I don't believe we should sell out to Big Pharma. They have a reason to shut this knoeledge down, to say nothing of the monetary loss for current shareholders. It would be much better to create a Canadian Big Pharma company that would give Canada the pharma independance we need (Covid showed us that.) and our youth the ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250